200 related articles for article (PubMed ID: 35983041)
1. Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review.
Shang J; Huang L; Huang J; Ren X; Liu Y; Feng Y
Front Immunol; 2022; 13():871372. PubMed ID: 35983041
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology.
Bajaj G; Suryawanshi S; Roy A; Gupta M
Br J Clin Pharmacol; 2019 Sep; 85(9):2045-2058. PubMed ID: 31140642
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review.
Zhao Y; Guo N; Zhu Y; Shang J; Chen J; Luo X; Liu Y; Zhang X; Huang L
Drug Des Devel Ther; 2024; 18():1771-1784. PubMed ID: 38828021
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors.
Sanghavi K; Zhang J; Zhao X; Feng Y; Statkevich P; Sheng J; Roy A; Vezina HE
CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):29-39. PubMed ID: 31709718
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours.
Melhem M; Hanze E; Lu S; Alskär O; Visser S; Gandhi Y
Br J Clin Pharmacol; 2022 Sep; 88(9):4142-4154. PubMed ID: 35357027
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of population pharmacokinetic analyses of polyclonal immunoglobulin G therapy.
Lee JL; Mohamed Shah N; Makmor-Bakry M; Islahudin F; Alias H; Mohd Saffian S
Int Immunopharmacol; 2021 Aug; 97():107721. PubMed ID: 33962225
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of therapeutic monoclonal antibodies.
Dirks NL; Meibohm B
Clin Pharmacokinet; 2010 Oct; 49(10):633-59. PubMed ID: 20818831
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
Desnoyer A; Broutin S; Delahousse J; Maritaz C; Blondel L; Mir O; Chaput N; Paci A
Eur J Cancer; 2020 Mar; 128():119-128. PubMed ID: 32037060
[TBL] [Abstract][Full Text] [Related]
9. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Hurkmans DP; Sassen SDT; de Joode K; Putter L; Basak EA; Wijkhuijs AJM; Joerger M; Debets R; Koch BCP; Van der Leest CH; Schreurs MWJ; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ; Koolen SLW
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088739
[TBL] [Abstract][Full Text] [Related]
10. A guide to rational dosing of monoclonal antibodies.
Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
[TBL] [Abstract][Full Text] [Related]
11. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
Shen T; James DE; Krueger KA
Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
[TBL] [Abstract][Full Text] [Related]
13. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies.
Zhang J; Sanghavi K; Shen J; Zhao X; Feng Y; Statkevich P; Sheng J; Roy A; Zhu L
CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):962-970. PubMed ID: 31710163
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
19. Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency.
Luo D; Baheti G; Tortorici MA; Hofmann J; Rojavin MA
Clin Ther; 2020 Jan; 42(1):196-209.e5. PubMed ID: 31910997
[TBL] [Abstract][Full Text] [Related]
20. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
Xiang H; Liu L; Gao Y; Ahene A; Collins H
Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
